News / Press Release

TD2 Receives Three-Year Renewal of AAALAC Accreditation

TD2 / July 18, 2018

We’re pleased to announce that our preclinical laboratory has again earned a Full Accreditation from AAALAC International Council.

TD2 has held AAALAC accreditation since 2010, and we’re thrilled that the 2018 renewal continues that succession through 2021.

In their letter of notification, the AAALAC Council on Accreditation made special recognitions of the following features of our preclinical facility, staff and resources:

 - Our administrative commitment to the program, along with the caliber of our documentation throughout it.

- The engagement of our Institutional Animal Care and Use Committee.

- The level of sanitation, cleanliness and organization in our facility.

- Our Occupational Health & Safety signage.

- Our tumor monitoring guideline.

- Our heating, ventilation and air conditioning monitoring system.

- Our storage and documentation practices for controlled substances.

 

We’re proud to support humane and responsible animal treatment throughout all ends of our scientific research, and we’re honored to continue this voluntary accreditation for years to come.

Want to learn more about our AAALAC-accredited preclinical lab? Ask us for a tour!

For more information, please contact
About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: